FDAnews Drug Daily Bulletin

THE WESTAIM CORPORATION ANNOUNCES PRICING FOR THE INITIAL PUBLIC OFFERING OF ITS NUCRYST PHARMACEUTICALS

Dec. 27, 2005
A A

The Westaim Corporation announced today the initial public offering of 4,500,000 common shares of its subsidiary NUCRYST Pharmaceuticals Corp. ("NUCRYST") at a price of US$10 per share. NUCRYST common shares will be traded on the Nasdaq National Market under the trading symbol NCST and on the Toronto Stock Exchange (in Canadian dollars) under the trading symbol NCS.

Canada NewsWire (http://www.newswire.ca/en/releases/archive/December2005/22/c3104.html)